Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

Argenx Ends Strong Stock Market Year 2025 with a Disappointment

Summary by De Tijd
09:03 The Ghent-based biotech company is in the final stages of halting a study to use its flagship drug efgartigimod to treat an eye disease. Shares on the Brussels stock exchange are expected to remain high until 9...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

De TijdDe Tijd

Argenx Ends Strong Stock Market Year 2025 with a Disappointment

09:03 The Ghent-based biotech company is in the final stages of halting a study to use its flagship drug efgartigimod to treat an eye disease. Shares on the Brussels stock exchange are expected to remain high until 9...

·Belgium
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

De Tijd broke the news in Belgium on Monday, December 15, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Technology icon

Technology

Ghent icon

Ghent

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal